ClinicalTrials.gov
ClinicalTrials.gov Menu

Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00624741
Expanded Access Status : No longer available
First Posted : February 27, 2008
Last Update Posted : June 22, 2012
Sponsor:
Information provided by (Responsible Party):
Valeant Pharmaceuticals International, Inc.

February 15, 2008
February 27, 2008
June 22, 2012
 
Compassionate Use Study of Pergolide in Patients With Parkinson's Disease
This compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.
Not Provided
Expanded Access
Drug: Pergolide
Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
Other Name: Permax
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
No longer available
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00624741
Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc.
Not Provided
Not Provided
Valeant Pharmaceuticals International, Inc.
June 2012